Biography
Steve Williams is currently responsible for Clinical R&D, Medical Affairs and Regulatory and Quality. He joined SomaLogic in 2009 as Chief Medical Officer responsible for the clinical application of the SomaScan® Platform and also had roles in launching the Life Sciences commercial business, assay development and bioinformatics. Prior to SomaLogic, Dr. Williams co-founded the pharma consultancy Decisionability, LLC in 2007 and authored the book “Decisionability.” From 1989-2007, he worked at Pfizer, Inc., initially in Experimental Medicine and later as Vice President and Worldwide Head of Clinical Technology. From 2003-2007, he was on the National Advisory Council for Biomedical Imaging and Bioengineering at the National Institutes of Health. He helped to launch the Alzheimer’s Disease Neuroimaging (ADNI) study and to form the FDA-FNIH-PhRMA biomarker consortium. He led or co-led the PhRMA position papers on “proof of concept,” surrogate endpoints and evidentiary standards for biomarkers and diagnostics.
Sequencing technologies are continuously improving, making it easier to obtain more in-depth molecular information than ever before. Emerging single-cell multi-omics sequencing technologies allow the capture of multiple modalities from a cell, including its epigenome, transcriptome, epitranscriptome, and proteome. This allows research into the heterogeneity of many biological mechanisms, and insights into complex molecular mechanisms that underpin disease.
Sessions: